Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: Results of the pharmacoepidemiologic CATS study

Social Psychiatry and Psychiatric Epidemiology

Volumn 48, Issue 8, 2013, Pages 1283-1288

  Deuschle, M ^a   Paul, F ^a   Brosz, M ^b   Bergemann, N ^c   Franz, M ^d   Kammerer Ciernioch, J ^e   Lautenschlager, M ^f   Lederbogen, F ^a   Roesch Ely, D ^a   Weisbrod, M ^g   Kahl, K G ^h   Reichmann, J ^b   Gross, J ⁱ   Umbreit, J ⁱ  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b StatConsult GmbH   (Germany)

^c Psychosomatic Clinic   (Germany)

^d Vitos Kurhessen Klinik für Psychiatrie und Psychotherapie Bad Emstal   (Germany)

^e Psychiatrisches Zentrum   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Klinikum Karlsbad Langensteinbach   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ PFIZER INC   (United States)

Author keywords

Cardiovascular risk; Metabolic syndrome; Schizophrenia; Screening; Treatment quality

Indexed keywords

BIOLOGICAL MARKER; LIPID; NEUROLEPTIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HUMAN; MALE; MASS SCREENING; MENTAL HOSPITAL; METABOLIC SYNDROME X; METABOLISM; METHODOLOGY; MIDDLE AGED; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; VERY ELDERLY; CARDIOVASCULAR DISEASES; COMPLICATION; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HOSPITALS, PSYCHIATRIC; HUMANS; LIPIDS; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; QUALITY OF HEALTH CARE; RISK FACTORS; SCHIZOPHRENIA;

EID: 84880834545     PISSN: 09337954     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00127-013-0676-0     Document Type: Article

References (36)

1. Osby U, Correia N, Brandt L, Ekbom A, Sparén P (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21-28
2. Wegelius A, Tuulio-Henriksson A, Pankakoski M, Haukka J, Lehto U, Paunio T et al (2011) An association between high birth weight and schizophrenia in a Finnish schizophrenia family study sample. Psychiatry Res 190:181-186
3. Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, Ben-Asher E et al (2012) Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample. PLoS One 7:e29228. doi: 10.1371/journal.pone.0029228
4. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B (2008) Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98:302-306
5. Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495
6. Chwastiak LA, Rosenheck RA, Kazis LE (2011) Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics 52:230-236
7. Gupta A, Craig TK (2009) Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc 18:200-207
8. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697-701
9. Vancampfort D, Probst M, de Herdt A, Corredeira RM, Carraro A, de Wachter D, de Hert M (2013) An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study. BMC Psychiatry 13:5. doi: 10.1186/1471-244X-13-5
10. Laursen TM, Munk-Olsen T, Vestergaard M (2012) Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25:83-88
11. Brown S, Mitchell C (2012) Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol 47:843-847
12. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
13. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K (2008) First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 192:406-411
14. Chaggar PS, Shaw SM, Williams SG (2011) Effect of antipsychotic medications on glucose and lipid levels. J Clin Psychiatry 51:631-638
15. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, de Hert M (2011) The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 26:291-302
16. Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl 1):20-27
17. Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical antipsychotic treatment or cardiometabolic risks? Acta Psychiatr Scand 119:171-179
18. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123:225-233
19. Oud MJ, Meyboom-de Jong B (2009) Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 10:32
20. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J (2009) Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 29:26-32
21. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW (2010) Metabolic testng rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 67:17-24
22. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS et al (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15-22
23. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ (2011) Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia. Br J Psychiatry 199:99-105
24. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272
25. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412-424
26. Mackin P, Bishop DR, Watkinson HM (2007) A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 7:28
27. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM (2005) Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 79:281-288
28. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW (2009) Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 166:345-353
29. Newcomer JW, Nasrallah HA, Loebel AD (2004) The atypical antipsychotic therapy and metabolic issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 24(Suppl 1):1-6
30. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, de Hert M (2012) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42:125-147
31. Deuschle M, Bergemann N, Kammerer-Ciernioch J, Franz M, Lautenschlager M, Lederbogen F et al (2008) Clinical analyses of the treatment of schizophrenia, CATS: Grundlagen einer pharmakoepidemiologischen Studie zur Qualität der Versorgung von Patienten mit Schizophrenie. Psychopharmakotherapie 15:147-152
32. Ford ES, Abbasi F, Reaven GM (2005) Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis 181:143-148
33. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):5-20
34. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19-32
35. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M (2011) Prevalence of metabolic syndrome an metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull. doi: 10.1093/schbul/sbr148
36. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutiérrez J, Navarro-Artieda R (2008) Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 23:100-108